within Pharmacolibrary.Drugs.ATC.N;

model N02CC04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.45,
    Cl             = 0.0006833333333333333,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.14,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013833333333333333,
    Tlag           = 15.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02CC04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist (triptan class) used in the acute treatment of migraine attacks with or without aura in adults. It is approved and widely used today for this indication.</p><h4>Pharmacokinetics</h4><p>Healthy adult subjects, single-dose pharmacokinetics after oral administration.</p><h4>References</h4><ol><li><p>Lee, Y, et al., &amp; Rogers, JD (1999). Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. <i>British journal of clinical pharmacology</i> 47(4) 373–378. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2125.1999.00917.x&quot;>10.1046/j.1365-2125.1999.00917.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10233200/&quot;>https://pubmed.ncbi.nlm.nih.gov/10233200</a></p></li><li><p>Shah, KA, et al., &amp; Cui, J (2022). Rizatriptan-Loaded Oral Fast Dissolving Films: Design and Characterizations. <i>Pharmaceutics</i> 14(12) –. DOI:<a href=&quot;https://doi.org/10.3390/pharmaceutics14122687&quot;>10.3390/pharmaceutics14122687</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36559181/&quot;>https://pubmed.ncbi.nlm.nih.gov/36559181</a></p></li><li><p>Shadle, CR, et al., &amp; Goldberg, MR (2000). A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers. <i>Journal of clinical pharmacology</i> 40(3) 309–315. DOI:<a href=&quot;https://doi.org/10.1177/00912700022008865&quot;>10.1177/00912700022008865</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10709161/&quot;>https://pubmed.ncbi.nlm.nih.gov/10709161</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02CC04;
